These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9469627)

  • 1. Hypercoagulability in heart failure.
    Jafri SM
    Semin Thromb Hemost; 1997; 23(6):543-5. PubMed ID: 9469627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The investigation of a heart valve patient with suspected hypercoagulability.
    Gough SC; Prentice CR
    J Heart Valve Dis; 1993 Jan; 2(1):7-17. PubMed ID: 8269113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolism and antithrombotic therapy in congestive heart failure.
    Dunkman WB
    J Cardiovasc Risk; 1995 Apr; 2(2):107-17. PubMed ID: 7606647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications.
    Kim JH; Shah P; Tantry US; Gurbel PA
    Curr Heart Fail Rep; 2016 Dec; 13(6):319-328. PubMed ID: 27815681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].
    Kohriyama T; Tanaka E; Katayama S; Yamamura Y; Nakamura S
    Rinsho Shinkeigaku; 1994 Aug; 34(8):771-6. PubMed ID: 7994982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure.
    Vila V; Sales VM; Almenar L; Lázaro IS; Villa P; Reganon E
    Thromb Res; 2008; 121(5):611-5. PubMed ID: 17692904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
    Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
    Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet activation in heart failure.
    Schäfer A; Eigenthaler M; Bauersachs J
    Clin Lab; 2004; 50(9-10):559-66. PubMed ID: 15481631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure, platelet activation and inhibition of the renin-angiotensin-aldosterone system.
    Bauersachs J; Schäfer A
    Arch Mal Coeur Vaiss; 2004 Sep; 97(9):889-93. PubMed ID: 15521482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevention of complications: a forgotten aspect of therapy? Thromboembolic complications].
    Simões L; Fontes P
    Rev Port Cardiol; 2001 Mar; 20 Suppl 3():27-31. PubMed ID: 11409071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy for heart failure in sinus rhythm.
    Subramaniam V; Davis RC; Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Dec; 23(6):705-17. PubMed ID: 19735305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet and fibrin metabolism in recipients of the Jarvik 7 total artificial heart.
    Ring ME; Feinberg WM; Levinson MM; Bruck DC; Smith RG; Icenogle TM; Copeland JG
    J Heart Transplant; 1989; 8(3):225-32. PubMed ID: 2525612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic therapy in heart failure: what conclusions can be drawn?
    Cokkinos DV
    J Cardiovasc Risk; 1995 Apr; 2(2):118-21. PubMed ID: 7606648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do we know about anticoagulation in patients with heart failure?
    Ahnert AM; Freudenberger RS
    Curr Opin Cardiol; 2008 May; 23(3):228-32. PubMed ID: 18382211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombosis and disorders of hemostasis in nephrotic syndrome].
    Kanfer A
    Nephrologie; 1992; 13(4):151-7. PubMed ID: 1407255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives].
    Scardi S; Mazzone C
    Ital Heart J Suppl; 2003 Mar; 4(3):201-9. PubMed ID: 12784754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
    Bellucci S; Ignatova E; Jaillet N; Boffa MC
    Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood coagulation system pathophysiology in acute myocardial infarction: the influence of anticoagulant treatment on laboratory findings.
    Fletcher AP; Alkjaersig NK; Ghani FM; Tulevski V; Owens O
    J Lab Clin Med; 1979 Jun; 93(6):1054-65. PubMed ID: 438607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation.
    Ohara K; Inoue H; Nozawa T; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2008 Jun; 126(3):316-21. PubMed ID: 17689760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.